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Objective
• To examine the eﬀect of penile vibratory stimulation (PVS)
in the preservation and restoration of erectile function and
urinary continence in conjunction with nerve-sparing
radical prostatectomy (RP).
Patients and Methods
• The present study was conducted between July 2010 and
March 2013 as a randomized prospective trial at two
university hospitals. Eligible participants were continent
men with an International Index of Erectile Function-5
(IIEF-5) score of at least 18, scheduled to undergo
nerve-sparing RP.
• Patients were randomized to a PVS group or a control
group. Patients in the PVS group were instructed in using a
PVS device (FERTI CARE® vibrator).
• Stimulation was performed at the frenulum once daily by
the patients in their own homes for at least 1 week before
surgery. After catheter removal, daily PVS was re-initiated
for a period of 6 weeks.
• Participants were evaluated at 3, 6 and 12 months after
surgery with the IIEF-5 questionnaire and questions
regarding urinary bother. Patients using up to one pad
daily for security reasons only were considered continent.
The study was registered at http://clinicaltrials.gov/
(NCT01067261).
Results
• Data from 68 patients were available for analyses (30
patients randomized to PVS and 38 patients randomized to
the control group).
• The IIEF-5 score was highest in the PVS group at all time
points after surgery with a median score of 18 vs 7.5 in the
control group at 12 months (P = 0.09), but the diﬀerence
only reached borderline signiﬁcance.
• At 12 months, 16/30 (53%) patients in the PVS group had
reached an IIEF-5 score of at least 18, while this was the case
for 12/38 (32%) patients in the control group (P = 0.07).
• There were no signiﬁcant diﬀerences in the proportions of
continent patients between groups at 3, 6 or 12 months. At
12 months 90% of the PVS patients were continent, while
94.7% of the control patients were continent (P = 0.46).
Conclusion
• The present study did not document a signiﬁcant eﬀect of
PVS. However, the method proved to be acceptable for most
patients and there was a trend towards better erectile
function with PVS. More studies are needed to explore this
possible eﬀect further.
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Introduction
Radical prostatectomy (RP) is a commonly employed
treatment for localized prostate cancer. Unfortunately, a
substantial proportion of patients will experience adverse
eﬀects in the form of urinary incontinence and erectile
dysfunction (ED) after the surgery [1]. The cavernous nerves
are responsible for inducing the physiological erection, and as
these nerves run in close proximity to the prostate gland, they
are in danger of being damaged during RP. Thus, it is well
accepted that the main pathophysiological mechanism behind
post-prostatectomy ED is damage to the cavernous nerves. To
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improve erectile function after surgery, nerve-sparing
procedures have therefore been developed, and whenever
tumour characteristics allow it, these are routinely employed
[2]. However, even when the cavernous nerves are left
anatomically intact, it is likely that they are aﬀected by
mechanical manipulation, heating, ischaemic eﬀects and local
inﬂammation [3,4]. This is believed to cause neuropraxia,
deﬁned as a temporary block of nerve transmission despite an
anatomically intact nerve ﬁbre. Postoperative incontinence can
be caused by damage to the urinary sphincter and changes in
the course of the urethra after surgery. However incontinence
can also occur if these structures are not compromised, which
could be connected to changes in the closing pressure of the
urinary sphincter and sometimes reduced bladder capacity
[5]. In these cases, it is likely that nerve damage plays a
pathophysiological role. Rehabilitation of patients’ sexual
function is often attempted with various regimens of
phosphodiesterase type 5 (PDE5) inhibitors, vacuum erection
devices and/or injection therapy [6–8]. Meanwhile,
rehabilitation regarding urinary continence is routinely
performed by instructing patients in pelvic ﬂoor exercises
before or after their surgery. Unfortunately, these
rehabilitation attempts are often unsuccessful and new
methods are needed [9,10]. One possible reason that current
methods have generally shown disappointing results in
preserving erectile function and continence is that they do not
target the pelvic nerves.
It has previously been shown that one can stimulate the nerves
of the pelvic ﬂoor by means of penile vibratory stimulation
(PVS). Thus PVS is capable of inducing ejaculations in ≈90%
of men with spinal cord injuries [11] and the treatment is
known to increase the pressure in the external urethral
sphincter as well as the bladder capacity in this patient group
[12,13]. In addition, mechanical nerve stimulation through
vibration applied at the perineum has shown promise in
treating urinary incontinence in women, with 24/33 (74%)
women experiencing complete resolution of symptoms after 6
weeks of stimulation [14]. Therefore it is feasible that this
method can improve nerve function and thereby prevent or
minimize the occurrence of incontinence and ED after pelvic
surgery. The purpose of the present study is to examine the
eﬀect of PVS in the preservation and restoration of erectile
function and urinary continence in conjunction with
nerve-sparing RP.
Patients and Methods
The study was conducted between July 2010 and March 2013
as a randomized controlled trial at two university hospitals.
Eligible participants were men scheduled to undergo
nerve-sparing RP. Only men who were sexually active with an
International Index of Erectile Function-5 (IIEF-5) [15] score
of at least 18 without erectogenic aids, and fully continent
before surgery (as assessed by the validated Danish Prostate
Symptom Score [DAN-PSS], were included in the study. The
DAN-PSS is a patient-administered questionnaire based on 12
symptoms related to bladder storage and voiding function and
describes both the severity and the perceived bother related to
each symptom [16]. To maintain a uniform patient group,
exclusion criteria included any condition that would prevent
the participant from attempting postoperative treatment with
a PDE5-inhibitor.
Data regarding preoperative erectile function (assessed by the
IIEF-5 questionnaire), and preoperative LUTS (assessed by the
DAN-PSS questionnaire) were collected at inclusion. Eligible
patients were then randomized by a draw using opaque
envelopes to either a PVS group or a control group. In both
groups, the patients received one preoperative session with
pelvic ﬂoor muscle training instruction. In addition, patients
in the PVS group were instructed in using a PVS device
(FERTI CARE® vibrator, Multicept A/S, Frederiksberg,
Denmark) during the same session (Fig. 1). The device was set
to an amplitude of 2 mm and a vibration frequency of 100 Hz.
Patients were instructed in stimulating the frenulum once
daily with a sequence consisting of 10 s of stimulation
followed by a 10-s pause repeated 10 times (for a total of 100 s
of stimulation every day). The patients were given a FERTI
CARE vibrator to use daily in their homes for at least 1 week
before surgery. In conjunction with surgery, the laterality of
nerve-sparing (unilateral/bilateral) was noted and patients
who underwent a non-nerve-sparing procedure were excluded
at this point. After the surgery, the remaining participants in
the PVS group were instructed to re-initiate the stimulation at
catheter removal and continue daily stimulation for a period
of 6 weeks. All participants in both groups were contacted by
Fig. 1 The FERTI CARE® vibrator. The vibratory stimulation of the device is
delivered through a reusable but disposable black plastic disc as seen
on the right side of the picture. The device was set to an amplitude of
2 mm and a vibration frequency of 100 Hz. Patients were instructed in
stimulating the frenulum once daily with a sequence consisting of 10 s of
stimulation followed by a 10-s pause repeated 10 times (for a total of
100 s of stimulation every day).
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phone to ensure compliance with pelvic ﬂoor exercises and
PVS at 2 and 6 weeks after surgery. At these contacts patients
in the PVS group were asked systematically about side-eﬀects
to the treatment. In both groups the patients were oﬀered
on-demand or daily PDE5 inhibitor treatment at 1 month
after surgery.
Participants were evaluated at 3, 6 and 12 months after surgery
with the IIEF-5 questionnaire for erectile function and
DAN-PSS for urinary bother. In addition, patients were asked
to rate their continence and to report their use of pads/diapers
at each visit. Patients reporting use of up to one pad daily for
security reasons only were considered continent.
The primary endpoint regarding erectile function was the
diﬀerence in median IIEF-5 score between the groups. The
primary endpoint regarding continence was time to
continence after surgery. Secondary outcome measures
included the number of patients who had achieved an IIEF-5
score of at least 18 with or without PDE5-inhibitors at 3, 6 and
12 months after surgery as well as the overall diﬀerence in
reported pad use and the diﬀerence in postoperative
DAN-PSS. In addition, we conducted post hoc multivariate
analyses to assess the inﬂuence of nerve-sparing and use of
PDE5 inhibitors on erectile function and to assess the
inﬂuence of nerve-sparing on continence.
The sample size was calculated based on the IIEF-5
questionnaire.With a two-sided signiﬁcance level set at 0.05, it
was calculated that 64 patients would be needed to detect a
minimally clinically meaningful diﬀerence of 5 with an sd of 6
and a power of 80%. To account for subsequent exclusion,
dropout and anticipated non-compliance, we aimed to include
80 patients in the preoperative phase.
The Wilcoxon–Mann–Whitney test was used to assess
diﬀerences in continuous variables, while Fisher’s exact test or
the chi-squared test was used to compare groups with regard
to categorical variables. For the multivariate analyses, we used
logistic regression. Outcome measures are presented as
percentages or as medians and range. All statistical tests were
performed with the SAS version 9.2 statistical software
package for windows (SAS Institute Inc., Cary, NC, USA). The
study was approved by the Danish ethical counsel and the
Danish Data Protection Agency. It was registered at
http://www.clinicaltrials.org (NCT01067261).
Results
A total of 91 eligible patients were identiﬁed and asked to
participate in the study and 83 patients were included before
surgery (42 randomized to the PVS group and 41 randomized
to the control group). In total, data from 68 patients were
available for analysis (30 patients randomized to vibration
therapy and 38 patients randomized to the control group).
Reasons for exclusion included non-nerve-sparing surgery (n
= 5), withdrawn consent (n = 3), loss of partner (n = 1) and
non-compliance with the PVS protocol (n = 6). Of the six
non-compliant patients, four could not use the device after
surgery because they had a catheter in place for an extended
period of time, while one felt pain on vibration. The last
patient stated that he did not feel comfortable with PVS. The
ﬂow of patients is illustrated in Fig. 2.
There were no statistically signiﬁcant diﬀerences in age, degree
of nerve-sparing, robotic/open surgery, preoperative IIEF-5
score or postoperative use of PDE5 inhibitors between the
groups; however, patients randomized to the PVS group had
Screened
(n = 91)
PVS group 
(n = 42)
Control group 
(n = 41)
Not included (n = 8) 
Declined to participate = 4
Surgery moved ahead = 4
Completed study
n = 30 (71%)
Discontinued (n = 12)
Non-nerve-sparing = 3
Withdrew consent = 2
Loss of partner = 1 
Non-compliance = 6
Completed study
n = 38 (93%)
Discontinued (n = 3)
Non-nerve-sparing = 2
Withdrew consent  = 1
Fig. 2 The flow of patients throughout the
study.
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signiﬁcantly more LUTS before surgery (P = 0.048) (Table 1).
There were no signiﬁcant diﬀerences in tumour stage (P =
0.7), Gleason score (P = 0.19) or preoperative PSA level (P =
0.66) between groups. Likewise, there were no statistically
signiﬁcant diﬀerences regarding any of the mentioned
variables between the ﬁnal 68 patients and the 10 patients who
were excluded for reasons other than a lack of nerve-sparing.
Follow-up data were available for 64/68 patients at 3 months,
67/68 patients at 6 months and 68/68 patients at 12 months.
The IIEF-5 score was higher in the PVS group at all time
points after surgery, but the diﬀerence between groups only
reached borderline signiﬁcance with a median (range) score of
18 (0–25) in the PVS group vs 7.5 (0–25) in the control group
at 12 months (Table 2). At 12 months after surgery, 16/30
(53%) patients in the PVS group had reached an IIEF-5 score
of at least 18, compared with 12/38 (32%) patients in the
control group (P = 0.07). There was also a non-signiﬁcant
trend towards more patients returning to an IIEF-5 score of at
least 18 at 6 months (P = 0.09) while there was no diﬀerence
in potency rates at 3 months after surgery (P = 0.46).
There were no signiﬁcant diﬀerences in the proportions of
continent patients between groups at either 3, 6 or 12 months
after surgery (Table 3). At 12 months, 90% of the PVS patients
were continent, compared with 94.7% of the control patients
(P = 0.46). There was a nonsigniﬁcant trend towards a higher
number of pads in the PVS group at 3 months, but there were
no diﬀerences at 6 and 12 months (Table 3). Likewise, there
were no signiﬁcant diﬀerences in total DAN-PSS between
groups at any point after the surgery (Table 4).
Due to the skewed preoperative DAN-PSS between the two
groups, post hoc analyses were conducted to assess whether the
preoperative DAN-PSS was associated with urinary outcomes.
These analyses showed that a high preoperative score was
associated with incontinence at 12 months (P = 0.035) and
with postoperative DAN-PSS at all time points during
follow-up.
The post hoc analysis regarding the inﬂuence of nerve-sparing
and the use of PDE5 inhibitors on erectile function showed a
similar picture to the univariate analysis, with an odds ratio of
regaining satisfactory erectile function at 12 months of 2.3
(95% CI: 0.8–6.4, P = 0.12) in the PVS group compared with
the control group. Likewise, nerve-sparing status did not
signiﬁcantly alter the eﬀect of PVS on continence outcomes, as
the odds ratio of regaining continence at 12 months was 0.44
(95% CI 0.07 – 2.9; P = 0.39) in the PVS group compared with
the control group on multivariate analysis. The laterality of
nerve-sparing was a signiﬁcant predictor of postoperative
erectile function, with an odds ratio of 3.5 (95% CI: 1.2 – 10.3)
for regaining satisfactory function with bilateral nerve-
sparing compared with unilateral nerve-sparing (P = 0.026).
Meanwhile, the use of PDE5 inhibitors did not inﬂuence
recovery of erectile function at 12 months (P = 0.4) and
nerve-sparing did not inﬂuence continence at 12 months
(P = 0.43).
Table 1 Patient characteristics.
Variables PVS Control P value
Median age, years 62 (46–73) 65 (49–76) 0.095
Nerve-sparing, n 0.23
Bilateral 19 18
Unilateral 11 20
Robot-assisted surgery, n 0.99
Yes 27 34
No 3 4
Median (range) preoperative IIEF-5 score 25 (19–25) 25 (18–25) 0.68
Median (range) preoperative DAN-PSS
score
3.5 (0–27) 2 (0–20) 0.048
Proportion of patients using
postoperative PDE5 inhibitors, n/N
3 Months 9/30 17/38 0.16
6 Months 19/30 25/38 0.72
12 Months 17/30 19/38 0.58
Table 2 Erectile function outcomes in the two groups after RP.
Erectile function
outcomes
PVS Control P value
Median (range) IIEF-5
At 3 months 5 (0–25) 5 (0–25) 0.25
At 6 months 10.5 (0–25) 5 (0–25) 0.08
At 12 months 18 (0–25) 7.5 (0–25) 0.09
IIEF ≥18, n/N (%)
At 3 months 5/30 (17) 4/38 (11) 0.46
At 6 months 13/30 (43) 9/38 (24) 0.09
At 12 months 16/30 (53) 12/38 (32) 0.07
Table 3 Continence rates and pad use after surgery.
PVS Control P value
Continence rate
At 3 months 65.5% 62.9% 0.83
At 6 months 83.3% 91.9% 0.28
At 12 months 90% 94.7% 0.46
Median (range) pad use
At 3 months 1 (0–6) 1 (0–4) 0.09
At 6 months 0 (0–3) 1/3 (0–6)* 0.14
At 12 months 0 (0–2) 0 (0–3) 0.56
*One patient reported using a third of a pad daily. As there was no pre-speciﬁed
decision on how to deal with such reporting, it was taken at face value when analysing
the results.
Table 4 Median (range) DAN-PSS after surgery.
PVS Control P value
Median (range) DAN-PSS
3 Months 1 (0–34) 5 (0–34) 0.74
6 Months 2 (0–41) 1 (0–48) 0.74
12 Months 3 (0–36) 0.5 (0–21) 0.13
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Out of the original 42 patients in the PVS group, ﬁve
experienced side-eﬀects related to the PVS. One described red
spots on the glans penis, while one patient had a small
laceration with minimal bleeding. In addition, two patients
described that they had become sore and another patient
experienced frank pain in the early postoperative period. All
side-eﬀects were self-limiting and no medical treatment
was required. However, as stated earlier, the patient who
experienced pain seized PVS because of this.
Discussion
Nerve-sparing and nerve regeneration are believed to be key
components with regard to post-prostatectomy functional
outcomes and the present study represents the ﬁrst attempt to
utilize nerve stimulation in a rehabilitation programme. The
neuroanatomical background is that aﬀerent nerve ﬁbres from
the glans penis run through the dorsal penile nerve to join
with ﬁbres from the pudendal nerve [17,18]. Through this
they reach the spinal cord at the spinal levels S2–S4 [17,18].
Conversely, parasympathetic ﬁbres from S2–S4 in the spinal
cord constitute the eﬀerent limb of the erectile response via
the cavernous nerve, while somatic ﬁbres running through the
pudendal nerve innervate the pelvic ﬂoor muscles and the
external urinary sphincter. Meanwhile, aﬀerent nerves
from the penis also reach the sympathetic centre in the
thoracolumbar part of the spinal cord where they might aﬀect
bladder contractility [19–21]. Possibly working through these
pathways, studies have identiﬁed several potential beneﬁts
from genital and perineal PVS, including ejaculation and
reduction of bladder overactivity in spinal cord-injured men
and an improvement in stress incontinence in women
[12,14,20]. The ﬁrst hypothesis of the current study was that
PVS in the early postoperative period after RP can stimulate
the cavernous nerves through the described reﬂex arch and
help in the restitution from neuropraxia. This, in turn, could
improve long-term erectile function. The second hypothesis
was that PVS could improve urinary control through
improved ability to contract the pelvic ﬂoor muscles and the
external urinary sphincter. Unfortunately we were unable to
identify a signiﬁcant eﬀect of 6 weeks of PVS after RP as
assessed by our primary outcome measures. The results
regarding urinary continence were particularly disappointing.
However, the study does show that the method is acceptable to
patients and that side-eﬀects are limited. In addition, the
trends towards better erectile function in the treatment group
imply that PVS might have some eﬀect on long-term erectile
function. Two post hoc analyses showed that results were not
altered signiﬁcantly when stratifying for laterality of
nerve-sparing and use of PDE5 inhibitors, as there was still a
trend towards better erectile function in the PVS group while
there was no eﬀect on urinary incontinence. These analyses
also conﬁrmed previous knowledge that nerve-sparing is
crucial for the return of erectile function. Surprisingly the
multivariate analyses did not show a signiﬁcant eﬀect of PDE5
inhibitors on erectile function. This is probably because most
patients tried PDE5 inhibitors, thus watering down the
statistical eﬀect.
The stimulation variables in the present study were chosen
based on previous research regarding urinary incontinence
in women [14] and on clinical data from treating post-
prostatectomy incontinence with PVS at our centre
(unpublished data). As described, PVS was reinitiated at
catheter removal ≈ 2 weeks after RP and the stimulation
period lasted 6 weeks. This means that the PVS treatment was
continued until about 2 months after the surgery. Previous
studies on recovery of urinary continence using electrical
stimulation or magnetic innervation after RP have generally
used similar short-term treatment algorithms [9,22].
Meanwhile, studies on penile rehabilitation have used
treatments lasting between 2 and 9 months after surgery
[23–30]. Interestingly, the study that used the shortest
rehabilitation regimen (50 mg of sildenaﬁl three times a week
for 2 months) found an apparent eﬀect on maintaining the
integrity of the penile tissue [24], while a study using penile
prostaglandin E1 injections three times a week for 3 months
found an apparent clinical eﬀect of the treatment [30].
Meanwhile, several studies using longer protocols showed no
clinical eﬀects [26–29]. This is indicative of the fact that we do
not yet know the optimal length of penile rehabilitation
programmes, and it could suggest that rehabilitation is most
important in the early postoperative period. In support of
this, animal studies indicate that penile changes are most
pronounced in the early postoperative period [31,32]. Taking
this knowledge into consideration in conjunction with the fact
that patient compliance with long-term penile rehabilitation
programmes is known to be poor [33], we decided to maintain
the relatively short treatment duration of 6 weeks after
catheter removal. The only adjustment to the previous PVS
protocol was that participants were instructed to begin
treatment at least 1 week before surgery. This was a pragmatic
decision, which was intended partly to optimize nerve
function before surgery and partly to get the patients used to
the PVS device.
Admittedly, the wisdom of stopping PVS ≈ 2 months after RP
can be questioned in retrospect, as a major drawback of the
present study is the lack of data regarding eﬀects of long-term
PVS after RP. Such knowledge would have been especially
interesting, as nerve regeneration after RP is known to be
slow. However, the focus of the present study was to
investigate a rehabilitation modality with broad clinical
applicability and, in this connection, it seemed prudent to start
by investigating the eﬀects of a relatively short period of
treatment. Considering the patient acceptance, it would now
be obvious to initiate studies of PVS extended for a period of
more than 6 weeks in post-prostatectomy sexual rehabilitation
and to experiment with longer daily treatment sessions.
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With regard to the clinical applicability, the inclusion of both
unilaterally nerve-spared and bilaterally nerve-spared patients
and the broad use of PDE5 inhibitors warrant discussion.We
allowed for these possible confounders in the design of the
study as we wanted to explore PVS in the actual clinical
setting after RP. Furthermore, ethical considerations prevented
us from denying participants from receiving PDE5 inhibitors
after surgery, as these drugs have been shown to be eﬀective in
this setting while eﬀects of PVS were unknown [34]. The lack
of signiﬁcant diﬀerences in the two variables between the two
groups suggests that it did not inﬂuence the results of the
present study. This is supported by our multivariate post hoc
analyses in which we stratify for these variables. However, it is
possible that there could, in fact, be a greater eﬀect of PVS
with more rigorous nerve-sparing and that the eﬀect could be
modiﬁed with daily administration of PDE5 inhibitors.
Unfortunately, the sample size does not allow for meaningful
post hoc analyses to explore these issues further.
Regarding the costs of PVS with the FERTI CARE vibrator,
each machine is priced at ≈ €500 while the disposable plastic
discs (see Fig. 1) are about €5 apiece. The device can be
cleaned and sterilized between patients and can thus be reused
several times. In the authors’ experience there is no set
maximum number of times a device can be reused. However,
the battery life goes down over time and patients have been
known to break the device (e.g. by dropping it or by taking it
into the shower). One disc is suﬃcient for each patient as
there is no signiﬁcant wear on these. However, they are
disposed of between patients for hygienic reasons.
The present study is the ﬁrst of its kind and while this must be
considered a signiﬁcant strength, the study is not without
weaknesses. Patients randomized to the PVS group had
signiﬁcantly more LUTS before surgery than the no-treatment
group. Subsequent analyses revealed that this probably had an
impact on postoperative urinary function, calling the results of
the present study into question with regard to this outcome. It is
also worthy of consideration that the SD was larger than
expected. This means that the study population might have
been too small to show a signiﬁcant diﬀerence between the
groups regarding erectile function, even if such a diﬀerence was
present. The trends toward more potent patients and higher
IIEF-5 scores at both 6 and 12 months in the PVS group
(Table 2) imply that this could be the case. In general, the
statistical eﬀect of small numbers is that there is an increased
risk of type 2 errors, meaning that an actual eﬀect of a speciﬁc
treatment could be missed. In this regard, one should be careful
not to interpret any P value >0.05 as evidence that the null
hypothesis is true in studies that might not be adequately
powered. Another limitation in the study is the lack of a placebo
treatment in the control group. However, due to the nature of
the intervention, it was not possible to create a believable sham
device, which could maintain blinding of the study subjects. For
the same reason, previous randomized studies with electrical
stimulation for post-prostatectomy incontinence and vacuum
erection devices or injection therapy in penile rehabilitation
have been conducted without placebo controls. In addition, it
can be speculated that potential placebo eﬀects of PVS applied
until 2 months after RP would have faded over time, resulting
in limited signiﬁcance 12 months after surgery.
While post-prostatectomy PVS cannot be recommended based
on the results of the present study, the borderline signiﬁcant
results of the study certainly justify further research in this area.
In this regard, it is obvious that alternative treatment regimens
are possible. In addition to an increase in the duration of the
treatment, modiﬁcations to the treatment protocol should be
considered. Studies have shown that stimulation of the
frenulum only is suﬃcient to activate the dorsal penile nerve
and induce ejaculation and urinary sphincter contractions in
most spinal cord-injured men [11,12]. However, a mode of
stimulation where both the ventral and dorsal sides of the
glans are stimulated could potentially increase this eﬀect, as it
has also been seen with spinal cord-injured men [35]. Other
modiﬁcations could include adjustments of the vibratory
amplitude and frequency. However, it must be cautioned that
experience from other patient groups suggests that the relatively
high amplitude employed in the present study is required to
induce a physiological response.
We report the ﬁrst experience with PVS in the recovery of
urinary continence and erectile function after nerve-sparing
RP. The present study did not document a signiﬁcant eﬀect of
6 weeks of postoperative PVS. However, the method proved to
be acceptable for most patients and there was a trend towards
better erectile function in patients who had undergone PVS.
More studies are needed to explore this possible eﬀect further.
In this regard, future research should attempt to make
adjustments to the PVS protocol.
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